CoChat

Development of retinal atrophy after subretinal gene therapy with voretigene neparvovec

Reichel, Felix Friedrich, Seitz, Immanuel, Wozar, Fabian, Dimopoulos, Spyridon, Jung, Ronja, Kempf, Melanie, Kohl, Susanne, Kortüm, Friederike Charlotte, Ott, Saskia, Pohl, Lisa, Stingl, Krunoslav, Bartz-Schmidt, Karl Ulrich, Stingl, Katarina, Fischer, M. Dominik · 2023 · British Journal of Ophthalmology
Cited by 79

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Background/aims: Voretigene neparvovec (VN) is the first and only subretinal gene therapy approved by the Food and Drug Administration and European Medicines Agency. Real-world application has started in 2018 in patients with vision impairment due to biallelic retinal pigment epithelium (RPE)65 mutation-associated inherited retinal degenerations. Herein, we evaluated the development of retinal atrophy within in a single-centre patient cohort treated with VN. Methods: 13 eyes of eight patients treated with VN were retrospectively analysed for areas of retinal atrophy over a period of 6–24 months following surgery. Ultrawide field images were used to measure the area of atrophy. Fundus autofluorescence imaging is presented as an instrument for early detection of signs of retinal atrophy in these patients. Results: Atrophic changes beyond the retinotomy site were observed in all eyes. Areas of atrophy developed within the area of detachment (bleb) in all eight patients and outside the bleb in three patients. Changes in autofluorescence preceded the development of retinal atrophy and were already evident 2 weeks after surgery in the majority of patients. The areas of atrophy increase with time and progression continued over year 1. Functional outcomes remained stable (VA, FST, visual field). Conclusion: Subretinal injection of VN can lead to RPE atrophy with consequent photoreceptor loss in and outside of the bleb area. Fundus autofluorescence is an important tool to monitor atrophic changes in patients after gene therapy. Interestingly, while areas of atrophy also included central areas, the functional benefits of the treatment did not appear to be affected and remained stable.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/bjophthalmol-2021-321023

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 79

Metadata

Authors
Reichel, F. F., Seitz, I., Wozar, F., Dimopoulos, S., Jung, R., Kempf, M., Kohl, S., Kortüm, F. C., Ott, S., Pohl, L., Stingl, K., Bartz-Schmidt, K. U., Stingl, K., & Fischer, M. D.
Venue
British Journal of Ophthalmology
Publisher
BMJ
Published
2022-05-24
Volume
107
Issue
9
Pages
1331-1335
ISSN
  • 0007-1161 (ISSN-L)
  • 1468-2079
OpenAlex
W4281382958
Cited by
79
References
8
FWCI
4.28
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Development of retinal atrophy after subretinal gene therapy with voretigene neparvovec. https://app.cochat.ai/papers/10.1136/bjophthalmol-2021-321023
The paper
Reichel, F. F., Seitz, I., Wozar, F., Dimopoulos, S., Jung, R., Kempf, M., Kohl, S., Kortüm, F. C., Ott, S., Pohl, L., Stingl, K., Bartz-Schmidt, K. U., Stingl, K., & Fischer, M. D. (2023). Development of retinal atrophy after subretinal gene therapy with voretigene neparvovec. British Journal of Ophthalmology. https://doi.org/10.1136/bjophthalmol-2021-321023

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.